A carregar...
Golimumab for the treatment of ulcerative colitis
Introduction: Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonis...
Na minha lista:
| Publicado no: | Expert Opin Biol Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490638/ https://ncbi.nlm.nih.gov/pubmed/28472597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1327576 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|